Beacon VP Investments
View Beacon VP Investments' Articles BY TICKER:
- AP Pharma's Drug Likely To Receive FDA Approval
- Theravance's Drug Breo Likely To Receive FDA Approval
-
Depomed's Drug Serada Ready For FDA Approval
- MAP's Levadex Ready For FDA Approval
- Raptor's Drug Procysbi Ready For FDA Approval
- Hyperion's Drug Ravicti Likely To Receive FDA Approval
- Hemispherx's Ampligen Is Unlikely To Receive FDA Approval
- Alexza's Adasuve May Not Be Ready For FDA Approval
- Exelixis's Cabozantinib Should Receive FDA Approval, But Faces Long-Term Challenges
- Despite Safety Concerns, Dynavax's Heplisav Should Receive FDA Approval
- Aegerion's Drug Lomitapide Should Receive FDA Approval